Ergocaff PB

Ergocaff PB is a combination small molecule medication formerly used for the treatment of migraine headaches, particularly in patients experiencing severe nausea and vomiting. It contains four active components: ergotamine tartrate, caffeine, pentobarbital, and belladonna alkaloids. Ergotamine acts as a vasoconstrictor by targeting serotonin receptors (5-HT1B/1D), while caffeine is included to enhance the absorption and efficacy of ergotamine. Pentobarbital serves as a sedative to address the agitation associated with migraines, and belladonna provides anticholinergic effects to mitigate nausea. Developed and manufactured by Centrix Pharmaceutical, the drug was available as a rectal suppository. In 2007, the FDA ordered the discontinuation of Ergocaff PB and similar unapproved ergotamine-containing products due to safety concerns regarding potential drug interactions and lack of formal approval.

Brand names

Ergocaff PB